KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Acquisitions (2020 - 2022)

Bionano Genomics (BNGO) has disclosed Acquisitions for 3 consecutive years, with $32.0 million as the latest value for Q4 2022.

Quarterly Acquisitions fell 34.73% to $32.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $31.3 million through Dec 2022, down 36.14% year-over-year, with the annual reading at $31.3 million for FY2022, 36.14% down from the prior year.
Acquisitions hit $32.0 million in Q4 2022 for Bionano Genomics, up from -$694000.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $49.1 million in Q4 2021 to a low of -$2.4 million in Q4 2020.
Historically, Acquisitions has averaged $19.5 million across 3 years, with a median of $15.7 million in 2022.
Biggest five-year swings in Acquisitions: soared 2103.51% in 2021 and later tumbled 34.73% in 2022.
Year by year, Acquisitions stood at -$2.4 million in 2020, then skyrocketed by 2103.51% to $49.1 million in 2021, then crashed by 34.73% to $32.0 million in 2022.
Business Quant data shows Acquisitions for BNGO at $32.0 million in Q4 2022, -$694000.0 in Q1 2022, and $49.1 million in Q4 2021.